

Indian Journal of Dermatology, Venereology & Leprology

CONTENTS

<p>Editor Uday Khopkar</p> <p>Associate Editors Ameet Valia Sangeeta Amladi</p> <p>EDITORIAL BOARD MEMBERS Sandipan Dhar Sanjeev Handa H. R. Jerajani Sharad Mutalik C. M. Oberai M. Ramam D. A. Satish Rajeev Sharma Shruthakirti Shenoj C. R. Srinivas D. M. Thappa S. L. Wadhwa</p> <p>Ex-officio Members A. K. Bajaj S. Sacchidanand</p> <p>EDITORIAL OFFICE Dr. Uday Khopkar Editor, IJDVL 2/7, Govt. Colony, Haji Ali, Mumbai-400034. E-mail: editor@ijdv.com</p> <p>PUBLISHED BY Medknow Publications 12, Manisha Plaza, M. N. Road, Kurla (W), Mumbai-400070, India. Phone: 91-22-25032970 Fax: 91-22-25032398 E-mail: publishing@medknow.com Website: www.medknow.com</p> <p>Manuscript submission www.journalonweb.com/ijdv</p> <p>Cover design courtesy Sudler & Hennessey</p>	<p>EDITORIAL</p> <p>PRESIDENTIAL ADDRESS</p> <p>REVIEW ARTICLE</p> <p>STUDIES</p> <p>CASE REPORTS</p>	<p>IJDVL at the crossroads</p> <p>A. K. Bajaj</p> <p>Serious cutaneous adverse drug reactions: Pathomechanisms and their implications to treatment Arun C. Inamdar, Aparna Palit</p> <p>Diltiazem vs. nifedipine in chilblains: A clinical trial A. K. Patra, A. L. Das, P. Ramadasan</p> <p>A comparative study of PUVASOL therapy in lichen planus Lata Sharma, M. K. Mishra</p> <p>Utility of polymerase chain reaction as a diagnostic tool in cutaneous tuberculosis Padmavathy L., Lakshmana Rao L., Veliath A. J.</p> <p>Therapeutic efficacy of intralesional triamcinolone acetonide versus intralesional triamcinolone acetonide plus lincomycin in the treatment of nodulocystic acne B. B. Mahajan, Geeta Garg</p> <p>Ichthyosiform sarcoidosis following chemotherapy of Hodgkin's disease M. P. S. Sawhney, Y. K. Sharma, V. Gera, S. Jetley</p> <p>Urticarial vasculitis in infancy Sukhjot Kaur, Gurvinder P. Thami</p> <p>Koebner phenomenon in PLEVA Arun C. Inamdar, Aparna Palit</p> <p>Familial acrogeria in a brother and sister Shaikh Manzoor Ahmad, Imran Majeed</p> <p>Cornelia de Lange syndrome K. Muhammed, B. Safia</p>	<p>_____ 203</p> <p>_____ 204</p> <p>_____ 205</p> <p>_____ 209</p> <p>_____ 212</p> <p>_____ 214</p> <p>_____ 217</p> <p>_____ 220</p> <p>_____ 223</p> <p>_____ 225</p> <p>_____ 227</p> <p>_____ 229</p>
---	--	---	---

Indian Journal of Dermatology, Venereology & Leprology

CONTENTS (CONTD.)

The Indian Journal of Dermatology, Venereology and Leprology is a bimonthly publication of the Indian Association of Dermatologists, Venereologists and Leprologists and published by Medknow Publications.

The Journal is indexed/listed with Health and Wellness Research Center, Health Reference Center Academic, InfoTrac One File, Expanded Academic ASAP, NIWI, INIST, Uncover, JADE (Journal Article Database), IndMed, Indian Science Abstract's and PubList.

All the rights are reserved. Apart from any fair dealing for the purposes of research or private study, or criticism or review, no part of the publication can be reproduced, stored, or transmitted, in any form or by any means, without the prior permission of the Editor, Indian Journal of Dermatology, Venereology and Leprology.

The information and opinions presented in the Journal reflect the views of the authors and not of the Indian Journal of Dermatology, Venereology and Leprology or the Editorial Board or the Indian Association of Dermatologists, Venereologists and Leprologists. Publication does not constitute endorsement by the journal.

The Indian Journal of Dermatology, Venereology and Leprology and/or its publisher cannot be held responsible for errors or for any consequences arising from the use of the information contained in this journal. The appearance of advertising or product information in the various sections in the journal does not constitute an endorsement or approval by the journal and/or its publisher of the quality or value of the said product or of claims made for it by its manufacturer.

For advertisements, please contact the Editor

	Intralesional steroid induced histological changes in the skin	
	Sukhjot Kaur, Amanjeet, Gurvinder P. Thami, Harsh Mohan	232
	Sparfloxacin induced toxic epidermal necrolysis	
	M. Ramesh, G. Parthasarathi, B. Mohan, A. B. Harugeri	235
	Fever due to levamisole	
	Ramji Gupta, Sameer Gupta	237
	Localized cutaneous sporotrichosis lasting for 10 years	
	Sanjay K. Rathi, M. Ramam, C. Rajendran	239
QUIZ	S. V. Rakesh, D. M. Thappa	241
RESIDENT'S PAGE	Sign of Nikolskiy & related signs	
	Deepa Sachdev	243
RESEARCH METHODOLOGY	Declaration of Helsinki: The ethical cornerstone of human clinical research	
	Gulrez Tyebkhan	245
MEDICOLEGAL WINDOW	Drug eruptions and drug reactions	
	Subodh P. Sirur	248
LETTERS TO EDITOR	Aggravation of preexisting dermatosis with <i>Aloe vera</i>	250
	Familial woolly hair in three generations	250
	Chronic pelvic inflammatory disease and melasma in women	251
	Comments on "Serological study for sexually transmitted diseases in patients attending STD clinics in Calcutta"	252
BOOK REVIEW	Colour atlas and synopsis of paediatric dermatology	
	Sandipan Dhar	255
ANNOUNCEMENTS		255, 256,
INSTRUCTIONS TO AUTHORS		258

Melasma was found in only 4 (3.15%) cases during pregnancy and in one with history suggestive of antepartum PID.

This study highlights that melasma in women is possibly due to photosensitivity in patients with chronic PID in a majority of cases. The association of melasma with pregnancy and oral contraceptives reported earlier was possibly due to increase proliferation of chlamydia during pregnancy due to lowered body immunity and milder nature of PID in those on oral contraceptives,⁷ respectively.

REFERENCES

1. Mosher DB, Fitzpatrick TB, Ortonne JP, Hori Y. Hypomelanosis and Hypermelanosis. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, et al, editors, Fitzpatrick's Dermatology in general medicine. 5th ed. New York: McGraw-Hill; 1999. p. 945-1018.
2. Winton GB, Lewis CU. Dermatoses of pregnancy. *J Am Acad Dermatol* 1982;6:977-8.
3. Rasnik S. Melasma induced by oral contraceptive drugs. *JAMA* 1967;199:95-9.
4. Perez M, Sanchez JL, Aguito F. Endocrinological profile of patients with idiopathic melasma. *J Invest Dermatol* 1981;81:543-5.
5. Smith AG, Shuster S, Thody AJ, Peberdy M. Chloasma, oral contraceptives, and plasma β -melanocytic-stimulating-hormone. *J Inves Dermatol* 1977;68:169-70.
6. Sawhney MPS. Chronic actinic dermopathy - A clinical study in Ladakh. *Indian J Dermatol Venereol Leprol* 2002;68:38-9.
7. Wolner-Hanssen P. Oral contraceptive use modifies the manifestations of pelvic inflammatory disease. *Br J Obstet Gynaecol* 1986;93:619-24.

M. P. S. Sawhney, R. Anand

Departments of Dermatology and STD and Obstetrics and Gynaecology, Command Hospital (EC), Kolkata-700027, India.

Address for correspondence: Lt. Col. M. P. S. Sawhney, Base Hospital, Barrackpore-700120, India. E-mail: mpssawhney@hotmail.com

Comments on "Serological study for sexually transmitted diseases in patients attending STD clinics in Calcutta"

Sir,

It was interesting reading "Serological study for sexually transmitted diseases in patients attending STD clinics

in Calcutta" published in *Indian J Dermatol Venereol Leprol* 2002; 68 275-278. We have some queries: comments for the authors to address.

What was the purpose of doing a qualitative VDRL test (which is more relevant in field conditions) in such a reputed institute of serology? A test with undiluted serum can result in false negativity because of the prozone phenomenon. Any titre cannot be considered significant (reactive). The VDRL test always has a standard cut off value for the uniform interpretation of results. However, the authors have not mentioned any such value in their article. In a developing country like India, various chronic infections can result in a false positive VDRL test in 1-3% of the patients. Further, a 'reactive' non-treponemal test indicates a present infection or a recently treated or untreated infection.¹ The result needs to be correlated with the medical history, examination and even with specific treponemal tests.

TPHA is a quantitative test reported in titre and so agglutination at a particular titre is more meaningful than mere agglutination. It is well known that a low degree of TPHA positivity will remain for years even in cases who have been adequately treated.² VDRL and TPHA tests indicate the same disease and adding them up falsely increases the total number of positive tests without any logical basis.

Serologic assays may be useful in detecting the prevalence of *Chlamydia trachomatis* infections of the genital tract in the community. Since 45-65% of patients may have IgG antibodies resulting from past infection, only a certain level of titre or demonstration of a four-fold rise in titre in a repeat sample is meaningful. Detection of IgM antibodies is more helpful in establishing acute chlamydia infections of the genital tract.³ The present test report does not make us any wiser.

The results section is confusing; tabulating one or more serological tests in various combinations does not give any meaningful information. The article does not give us any idea about what the authors want to convey - single sample seropositivity without any cut off value?

It is commendable that the authors have tried to study the serum sample of such a large number of STD clinic attendees. However, a better-designed and interpreted study would have resulted in more useful information especially coming from such a leading centre. We hope our comments will be taken in the spirit they are meant to be.

REFERENCES

1. Ray K, et al. Screening and confirmation of syphilis by serology – a five years experience. *Ind J Sex Transm Dis* 1991;12:47-50.
2. Young H. Syphilis-Serology *Dermatol Clin* 1998;16:691-198.
3. MA Chernesky. *Chlamydia trachomatis* diagnostics. *Sex Transm Inf* 2002;78:232-4.

Sunil Dogra, Bhushan Kumar

Address for correspondence: Dr. Bhushan Kumar, Prof. and Head, Department of Dermatology Venerology and Leprology, PGIMER, Chandigarh-160012, India. E-mail: kumarbhushan@hotmail.com

Response by the author

Sir,

With reference to the queries of Dr. Dogra and Dr. Kumar on our article “Serological study for sexually transmitted diseases in patients attending STD clinics in Calcutta”, our comments on the various points raised by them are as follows:

1. As had been clearly mentioned in the Introduction, one of the main objectives of the study was “to ascertain the prevalence of syphilis, hepatitis B, chlamydia and HIV infection among patients attending different STD clinics in Calcutta”.
2. Since the VDRL test is a low cost, rapid and a good screening test, all the samples were first subjected to qualitative tests and samples showing reactivity were then further subjected to a quantitative test. In fact, it has been clearly mentioned in the article, under Materials and Methods that “Quantitative test was performed on all reactive sera including those showing weak or rough reaction”. Moreover, all the VDRL reactive sera, including all biological false positive sera were subjected to the TPHA test, which is a very specific test.
3. As mentioned under Materials and Methods, the TPHA test was performed using TPHA 200 kits, manufactured by Newmarket Laboratories Ltd., UK, strictly as per the manufacturer’s instructions. If one goes through the literature of the kit in detail, it will be observed that the final dilution of the sample is 1:80. Hence this is again a quantitative test and not qualitative. This is the standard method for the TPHA test.
4. About the comment that adding up VDRL and TPHA tests “falsely increases total number of positive tests without any logical basis”, it appears that the data has been misinterpreted. It must be clarified that Table V showing two tests positive, i.e. VDRL+TPHA, indicates that the same sample was positive for both VDRL as well as TPHA. So there is no question of increasing the total number.
5. Yes, we agree that IgM antibodies are more helpful in establishing acute chlamydia infections of the genital tract, but the present study was undertaken more from the epidemiological point of view. The values obtained from this assay are intended to be an aid for diagnosis only.
6. Table II clearly shows positivity for different serological tests among different age groups, infection being most commonly observed in the 15-30 years age group (20.13%), followed by the 30-45 years age group (12.69%) and the > 45 years age group (4.38%). It thus shows that the 15-30 years age group is the most vulnerable, and because of their risky behavior, this age group is susceptible to multiple infections.
7. Single sample positivity proves that only one infection was positive. All the serological tests, viz. HBsAg, TPHA, chlamydia-IgG, were done by kits, as per the manufacturers’ instructions and guidelines. The HIV test was done at the School of Tropical Medicine, which is a NACO centre for HIV detection. All the sera were tested by the ELISA method, using kits from INNOTEST HIV-1/HIV-2 Sp. Innogenetics N.V., Belgium. ELISA reactivities were confirmed